If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

The iTREAT study will compare different guideline approved ways of treating adults and teens with asthma to see if they reduce the need for emergency care or hospital visits. Some participants will use their controller inhaler with or instead of a reliever inhaler. Others will take an antibiotic pill and some participants will use both. Participation lasts for 16 months. Every other month you will answer questions about your asthma through an online or telephone survey.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

The purpose of this research study is to examine Black women's identity expressions within higher education and how this contributes to their persistence. It further examines how these scholars engage modes of Black finesse to overcome visibility challenges, confront intellectual devaluation, leverage their academic advising relationships, and cultivate joy within these spaces.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.

The standard treatment for newly-diagnosed multiple myeloma (NDMM) is autologous stem cell transplantation (ASCT). For this procedure, a patient's own healthy, blood-forming cells are collected. The patient then receives high-dose chemotherapy or radiation to kill the cancer cells. Then their healthy cells are returned to their body to recover. While ASCT is effective for many patients, it has significant side effects and may not be the best option for every patient with NDMM. In this research study, participants will receive one of two (2) study treatments: a new regimen of elranatamab plus daratumumab or a conventional regimen of ASCT plus lenalidomide and daratumumab. The delayed use of ASCT, as explored in this research study, is experimental and not standard-of-care.

Are you having foot fusion surgery? Join our study to help us learn how people heal and move after this kind of surgery. Your experience could help improve care for others with foot arthritis.

How did Helene affect you? If you are a voter in Avery, Buncombe, Henderson, Mitchell, or Yancey counties, we want to hear from you! Complete this 10-min survey for a chance to win 1 of 15 $25 gift cards

Do you have a shoulder or arm injury diagnosed with an MRI? Or are you healthy and active? Join our study to help us learn how well ultrasound works compared to MRI for finding muscle and tendon problems. Your help can improve sports injury care in the future.